Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Curium

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
From Curium
Via GlobeNewswire
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
From Curium
Via GlobeNewswire
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
From Curium
Via GlobeNewswire
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
From Curium
Via GlobeNewswire
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
From Curium
Via GlobeNewswire
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
From Curium
Via GlobeNewswire
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
From Curium
Via GlobeNewswire
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
From Curium
Via GlobeNewswire
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
From Curium
Via GlobeNewswire
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
From Curium
Via GlobeNewswire
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
From Curium
Via GlobeNewswire
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
From Curium
Via GlobeNewswire
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
From Curium
Via GlobeNewswire
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
From Curium
Via GlobeNewswire
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
From Curium
Via GlobeNewswire
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
From Curium
Via GlobeNewswire
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
From Curium
Via GlobeNewswire
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
From Curium
Via GlobeNewswire
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific
From Curium
Via GlobeNewswire
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
From Curium
Via GlobeNewswire
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
From Curium
Via GlobeNewswire
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
From Curium
Via GlobeNewswire
Curium’s Customers to Benefit From Mo-99 Production Restart
From Curium
Via GlobeNewswire
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
From Curium
Via GlobeNewswire
Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
From Curium
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.